🟠 Moderate Evidence
Sierra Leone is experiencing an unprecedented mpox crisis, with confirmed cases surging from minimal prior presence to over 4,400 infections within six months in 2025, according to analysis published in BMJ Global Health. The rapid escalation challenges previous epidemiological assumptions about mpox in West Africa and exposes critical gaps in vaccine equity, disease surveillance, and regional health system preparedness across the Mano River Union—a four-nation bloc comprising Sierra Leone, Liberia, Guinea, and Côte d’Ivoire.
Key takeaways
- Over 4,400 confirmed mpox cases in Sierra Leone within 6 months, representing a dramatic departure from historical baseline
- Vaccine deployment has been fragmented and delayed despite global commitments to equitable access
- Systemic failures in global health financing and governance disproportionately affect endemic African regions
- Coordinated regional response and decentralised testing infrastructure are urgently needed
Analysis at a Glance
| Source | BMJ Global Health |
| Article type | Regional epidemiological analysis |
| Geographic focus | Sierra Leone and Mano River Union (Liberia, Guinea, Côte d’Ivoire) |
| Time period | 2025 outbreak (6-month surge) |
| Key metric | 4,400+ confirmed mpox cases |
The Mpox Crisis Spans Four West African Nations
Sierra Leone and its Mano River Union neighbours face interconnected epidemic pressure and fragmented vaccine access
Source: BMJ Global Health, 2025 | Georgian Medical Journal News
An Unprecedented Outbreak in West Africa
The 2025 mpox outbreak in Sierra Leone represents a departure from historical patterns in the region, according to the analysis published in BMJ Global Health. Prior to 2025, mpox cases were minimal or absent; the rapid escalation to over 4,400 confirmed infections signals a fundamental shift in disease epidemiology and transmission dynamics in West Africa.
This surge has exposed critical vulnerabilities shared across the Mano River Union—a regional trade and health cooperation bloc that includes Liberia, Guinea, and Côte d’Ivoire alongside Sierra Leone. The interconnected nature of these economies and populations means that disease containment in one nation directly affects preparedness in neighbouring countries. According to the BMJ Global Health analysis, demographic and geographic patterns of transmission suggest that traditional disease surveillance systems were inadequate to detect and respond to the scale and speed of spread.
Vaccine Equity Failures in a Critical Hour
Despite repeated global commitments to equitable vaccine access—most prominently through World Health Organization declarations and international health partnerships—Sierra Leone and neighbouring nations have experienced significant delays and fragmented deployment of mpox vaccines, according to the BMJ Global Health report. These gaps reflect deeper systemic failures in global health financing mechanisms, vaccine supply chains, and governance structures that consistently disadvantage endemic and resource-limited African regions.
The analysis identifies vaccine access disparities as symptomatic of broader inequities: wealthy nations secured early vaccine supplies while lower-income West African countries awaited donations or bilateral agreements. The report calls for integration of mpox control into existing sexual health programmes and emphasises that targeted vaccination strategies must be tailored to local epidemiological patterns and population vulnerability, rather than applying standardised global protocols. See Health Policy coverage for related vaccine access analysis.
Surveillance and Diagnostics: The Foundation of Response
Operational challenges in disease surveillance and laboratory diagnostics have hampered outbreak control across the region, the BMJ Global Health analysis documents. Centralised testing capacity created bottlenecks: samples travelled long distances to reference laboratories, delaying confirmation and contact tracing. The authors emphasise that decentralised diagnostic infrastructure—moving testing closer to affected communities—is essential for real-time outbreak detection and rapid public health response.
Strengthening African vaccine manufacturing capacity is identified as a critical long-term investment. The analysis notes that dependence on external vaccine supply renders endemic regions perpetually vulnerable to global supply shocks and geopolitical delays. Regional manufacturing partnerships could ensure sustained, locally appropriate vaccine availability and reduce the lag between outbreak emergence and immunisation campaigns. Learn more in Global Health and scientific research coverage.
The 2025 mpox outbreak in Sierra Leone and the Mano River Union demonstrates that previous assumptions about mpox epidemiology in West Africa were inadequate, and that systemic failures in global health governance create predictable vulnerabilities in endemic regions.
— BMJ Global Health analysis, 2025
What this means
Frequently asked questions
Why did mpox cases surge so rapidly in Sierra Leone in 2025?
According to the BMJ Global Health analysis, the outbreak represents a departure from historical patterns, suggesting either a change in transmission dynamics, improved case detection following baseline surveillance expansion, or both. The analysis notes that demographic and geographic patterns of infection differ from previous mpox epidemiology in West Africa, pointing to factors such as transmission networks and population susceptibility that warrant further investigation.
What are the main barriers to mpox vaccine access in West Africa?
The report identifies systemic failures in global health financing, fragmented vaccine ecosystems, and governance structures that prioritise high-income nations. Delays in bilateral agreements, uneven donation pipelines, and lack of local manufacturing capacity compound the problem. Integration of vaccine campaigns into existing sexual health infrastructure and regional procurement coordination are proposed solutions.
How can decentralised testing improve outbreak control?
Moving diagnostic capacity closer to affected communities reduces the time-to-result for case confirmation, enabling faster contact tracing and isolation. The BMJ Global Health analysis notes that centralised laboratory systems created bottlenecks that delayed public health action; decentralised molecular and clinical diagnostic capacity would accelerate detection and reduce transmission opportunities.
The 2025 mpox crisis in Sierra Leone and the Mano River Union serves as a critical test case for global health governance reform. The analysis published in BMJ Global Health argues that rethinking financing mechanisms, strengthening African vaccine manufacturing, and ensuring timely, equitable support for endemic regions is not merely a matter of public health ethics—it is essential pandemic preparedness infrastructure that benefits all nations. The coming months will reveal whether international commitments translate into coordinated, equity-driven regional response or whether systemic inequities persist.
Source: Mpox in Sierra Leone and the Mano River Union: an epidemic unfolding in real time, BMJ Global Health, 2025
Was this article helpful?
Related Coverage
